C83.24 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, lymph nodes of axilla and upper limb

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, lymph nodes of axilla and upper limb
• Also known as ICD-10 code C83.24

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in the lymph nodes of the axilla and upper limb, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in the axilla or upper limb.
• Unexplained weight loss.
• Fever.
• Night sweats.

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT or MRI) to assess lymph node involvement, and biopsy of the affected lymph node. Histopathological analysis confirms the presence of mixed small and large cell morphology, and immunohistochemistry or flow cytometry may be used to identify cell lineage (B-cell or T-cell). Staging studies, such as PET scans, help determine the extent of disease.

Treatment Options

Treatment depends on the stage and aggressiveness of the lymphoma and may include chemotherapy, immunotherapy, radiation therapy, or a combination of these. Targeted therapies or clinical trial participation may be considered for specific cases. Treatment plans are individualized based on patient health and lymphoma characteristics.

Prognosis and Follow-Up

Prognosis varies based on factors like age, overall health, and lymphoma stage. Regular follow-up with imaging and clinical assessments is standard to monitor for recurrence or progression. Long-term surveillance is important, as late effects or secondary malignancies may occur.

Complications

Potential complications include disease progression, treatment-related side effects (e.g., infection risk from immunosuppression), organ dysfunction from lymphoma spread, or transformation to a more aggressive subtype.

Lifestyle & Prevention

While prevention is not fully established, maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known carcinogens (e.g., tobacco) may support overall health. Managing chronic infections or immunosuppressive conditions under medical guidance is advisable.

When to Seek Professional Help

Seek medical attention for persistent swollen lymph nodes, unexplained weight loss, fever, or night sweats. Prompt evaluation is important for early diagnosis and treatment planning.

Tips for Medical Coders

Document the specific location (axilla and upper limb lymph nodes) and confirm the mixed small and large cell (diffuse) morphology. Ensure clinical correlation with biopsy results and staging details to support accurate coding. Note that this code is site-specific and should not be used for unspecified or other regional lymph node involvement.